在心力衰竭中使用β-阻塞剂与保存的喷射分数:当代管理中的作用正在下降
Nathaniel Abittan1, Ashish Tripathi2, Ryan Cheikhali2
1From the Department of Cardiology and Medicine.
Cardiology in review
|June 27, 2025
概括
维护喷射分数 (HFpEF) 的心力衰竭中使用β抑制剂 (BBs) 是有争议的. 虽然对伴随性疾病有益,但BBs可能会使某些HFpEF患者的症状恶化,需要进一步研究.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 保存喷射分数 (HFpEF) 的心力衰竭是一个日益增长的临床挑战,占心力衰竭诊断的近一半.
- HFpEF的特点是扩张功能受损,运动能力降低和死亡率增加,特别是在患有并发病的老年患者中.
研究的目的:
- 综合当前关于β-阻断剂 (BB) 在HFpEF中的使用数据.
- 探索HFpEF中BBs的机制论证,临床指示和潜在危害.
- 为了澄清BBs在HFpEF管理中的不确定的和有争议的角色.
主要方法:
- 这篇叙事综述综合了来自随机试验,观察研究和元分析的现有数据.
- 它检查了在HFpEF中使用BB背后的机制逻辑.
- 该审查澄清了临床指示和潜在的不良影响.
主要成果:
- 从历史上看,BBs在心力衰竭中使用了减少喷射分数 (HFrEF),并证明了其死亡率的好处.
- 在HFpEF中,BBs用于心房动和缺血性心脏病等并发症.
- 新兴研究表明,BBs可能会放大慢性无能症,并降低某些HFpEF表型的心脏输出,可能会使症状恶化.
结论:
- 在HFpEF中BBs的作用仍然不确定和有争议.
- 虽然BBs可以应对并发症,但在特定的HFpEF群体中,它们的使用可能会带来风险.
- 进一步的有针对性的研究对于在HFpEF中定义适当的BB使用至关重要.
更多相关视频
09:20Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
Published on: February 13, 2021
6.6K
14:35Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
Published on: April 17, 2021
8.7K
相关概念视频
01:22Heart Failure Drugs: β-Blockers
441
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
441
01:30Heart Failure V: Medical Management
33
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
33
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
524
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
524
01:30Heart Failure IV: Classification and Diagnostic Evaluation
41
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
41
01:27Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
1.0K
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
1.0K
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
635
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
635